Final Results

AI SummaryClose X

Fusion Antibodies plc reported final results for the year ended March 31, 2026, with audited revenues of £2.1 million, an increase from £1.97 million in the prior year, driven partly by an intellectual property transfer. The company achieved a significant gross margin improvement to 53% from 22% in FY2025, while its operating loss narrowed to £1.13 million from a restated £1.63 million, despite increased R&D investment. Other operating income, primarily from a grant programme, was £872,000. The company also successfully launched its OptiMAL® product in December 2025 and ended the year with £1.04 million in cash, up from £0.36 million.

Disclaimer*

UK 100

Latest directors dealings